Amicus Therapeutics Inc to Discuss the Topline PROPEL Results - Conference Call Transcript
Good afternoon, ladies and gentlemen, and welcome to the Amicus Therapeutics' conference call and webcast. (Operator Instructions) As a reminder, this conference call is being recorded. I would now like to turn the conference over to your host, Mr. Andrew Faughnan, Head of Investor Relations. You may begin.
Thanks, Gigi. Good afternoon. Thank you for joining our conference call to discuss top line results from the Phase III PROPEL study of AT-GAA, Amicus' novel therapy for the treatment of late onset Pompe disease. Speaking on today's call, we have John Crowley, Chairman and Chief Executive Officer; Dr. Jeff Castelli, Chief Development Officer; and Dr. Mitch Goldman, Senior Vice President and Head of Clinical Research. Also joining for Q&A from Amicus are Bradley Campbell, President and Chief Operating Officer; Daphne Quimi, Chief Financial Officer; and Dr. Hung do, Chief Science Officer.
As referenced on Slide 2, we may make forward-looking statements within the meaning of the Private
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |